| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Grant receivable | NaN | 952,460 | 198,296 | 176,122 |
| Cash | 12,835,454 | 17,813,521 | 2,835,916 | 7,374,815 |
| Reimbursement right | 2,297,806 | 2,297,806 | NaN | NaN |
| Due from related party | 638 | 638 | NaN | NaN |
| Prepaid expenses and other current assets | 1,615,096 | 919,440 | 1,716,836 | 690,784 |
| Total current assets | 16,748,994 | 21,983,865 | 4,751,048 | 8,241,721 |
| Property and equipment, net of depreciation | 346,745 | 370,681 | 19,908 | 24,689 |
| Goodwill | 25,744,143 | 25,744,143 | NaN | NaN |
| Intangible assets | 114,300,000 | 114,300,000 | NaN | NaN |
| Deferred offering costs | 25,000 | NaN | 455,726 | NaN |
| Total assets | 157,164,882 | 162,398,689 | 5,226,682 | 8,266,410 |
| Accounts payable and accrued expenses | 5,293,308 | 3,494,220 | 2,967,828 | 1,564,990 |
| Deferred grant income | NaN | NaN | NaN | 0 |
| Total current liabilities | 5,378,570 | 3,494,220 | 2,967,828 | 1,564,990 |
| Warrant liability | 559,747 | 434,399 | 832,875 | 553,714 |
| Contingent consideration | 6,248,000 | 6,364,000 | NaN | NaN |
| Deferred tax liability | 457,377 | 226,068 | NaN | NaN |
| Long-term liabilities | 7,265,124 | 7,024,467 | 832,875 | 553,714 |
| Total liabilities | 12,643,694 | 10,518,687 | 3,800,703 | 2,118,704 |
| Series a non-voting convertible preferred stock - 0.0001 par value per share 1,242.0718 shares authorized at march 31, 2026, and december 31, 2025 1,212.1822 shares issued and outstanding at march 31, 2026, and december 31, 2025 | 143,269,761 | 141,544,536 | NaN | NaN |
| Non-voting convertible preferred stock | 121 | NaN | NaN | NaN |
| Common stock - 0.0001 par value per share 290,000,000 shares authorized at march 31, 2026, and december 31, 2025 916,968 shares issued and outstanding at march 31, 2026, and december 31, 2025 | 92 | 92 | 84 | 84 |
| Additional paid-in capital | 116,899,277 | 108,198,366 | 85,845,777 | 85,711,453 |
| Accumulated deficit | -115,648,063 | -97,862,992 | -84,419,882 | -79,563,831 |
| Total stockholders' equity | 1,251,427 | 10,335,466 | 1,425,979 | 6,147,706 |
| Total liabilities, series a non-voting convertible preferred stock and stockholders' equity | 157,164,882 | 162,398,689 | 5,226,682 | 8,266,410 |
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)